A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer

Conclusion.Selinexor demonstrated clinical activity and poor tolerability in mCRPC patients refractory to second‐line anti‐androgenic agents.

Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Xiao X. Wei, Adam P. Siegel, Rahul Aggarwal, Amy M. Lin, Terence W. Friedlander, Lawrence Fong, Won Kim, Mirela Louttit, Emily Chang, Li Zhang, Charles J. Ryan Tags: Prostate, Chinese Edition, Clinical Trial Results, Genitourinary Cancer Source Type: research